Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Barron Von Hymen who wrote (229)	5/19/1998 7:49:00 PM
From: Maxer	Respond to of 642

<<This is over reaction, we're down over 2%.>> Probably so. Volume is much lower than average- movement not so meaningful.

To: Barron Von Hymen who wrote (229)	5/26/1998 12:11:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 642

LILLY AND TAKEDA TO COLLABORATE ON NOVEL ORAL AGENT AND A FUTURE PR Wire May 26, 1998, 6:21 a.m. PT Insulin Product for the Treatment of Diabetes INDIANAPOLIS, May 26 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Takeda Chemical Industries, Ltd., announced today that they have entered into a marketing collaboration to copromote Takeda's novel insulin sensitivity enhancer pioglitazone (pronounced "pie-oh-gli-tah-zone") and a future product from the Lilly insulin portfolio in the United States. Pioglitazone has been submitted for regulatory approval in Japan by Takeda and currently is in Phase III clinical trials in the U.S. and Europe. Pioneered by Takeda, the thiazolidinedione class of insulin sensitivity enhancers - TZDs - represent a new treatment for patients with type 2 diabetes because of the TZD's improved product profile and unique mechanism of action. Upon approval, pioglitazone will enter the oral-agent category that had U.S. sales of approximately $1.5 billion in 1997, with sales growing at an estimated annual rate of more than 30 percent. Under the collaboration, Lilly and Takeda will copromote Takeda's pioglitazone, upon approval by the FDA to market it in the U.S., and a future Lilly insulin prior to pioglitazone's approval. In doing so, Takeda will form its own independent affiliate in the U.S. Both Lilly and Takeda will primarily be compensated through a copromotion fee - a percentage of net sales of the other party's respective product that is part of this collaboration. "We are delighted to have this opportunity to work with Takeda because we share a similar vision and commitment to innovation and globalization," said Sidney Taurel, Lilly president and chief operating officer. "Takeda is a highly respected pharmaceutical company throughout the world and will make an excellent partner for this important marketing collaboration - which we want to become a model for future alliances of this kind." "We are very excited about teaming up with Lilly, a long-standing leader in diabetes care," said Kunio Takeda, Takeda's president and chief executive officer. "We want to develop this alliance into the most successful one in history." Today, worldwide costs for treating diabetes are estimated at more than $200 billion annually, and it is estimated that, over the next decade, those costs could double due to the related complications of diabetes, such as kidney damage, limb amputation and problems with eyesight. James A. Harper, president of Lilly's diabetes care and growth and recovery products, said, "Lilly is aggressively pursuing a goal of being a complete diabetes care company. We intend to provide innovative pharmaceutical products that can treat all types and stages of diabetes globally. This collaboration with Takeda fits well with Lilly's strategy." Takeda is an R&D-oriented corporation specializing in pharmaceuticals and is the largest pharmaceutical company in Japan. Its main ethical drug products, leuprolide (GnRH analogue) and lansoprazole (proton pump inhibitor), are marketed in more than 70 countries. Lilly is a global research-based pharmaceutical corporation headquartered in Indianapolis, Ind., that is dedicated to creating and delivering innovative pharmaceutical-based health-care solutions which enable people to live longer, healthier and more active lives. Diabetes is one of five therapeutic areas in which the company is focusing its efforts. This release contains forward-looking statements about the potential clinical profile and commercial success of the investigational compound pioglitazone. As with any pharmaceutical product, there are risks and uncertainties that could cause actual results to differ. In particular, there is no assurance that regulatory approvals will be obtained, that final clinical trial results will be consistent with interim results to date, or that patient and physician acceptance of the product will be achieved. SOURCE Eli Lilly and Company -0- 05/26/98 /CONTACT: Blair Austin of Eli Lilly, 317-277-5170/ /Company News On-Call: prnewswire.com or fax, 800-758-5804, ext. 126236/ /Web site: lilly.com (LLY) CO: Eli Lilly and Company; Takeda Chemical Industries, Ltd. ST: Indiana IN: MTC SU: -0- (PRN) May/26/98 09:06 EOS (PRN) May/26/98 09:06 86 -0- (PRN) May/26/ 98 9:21